Thermo Fisher Scientific to Implement Darwin LIMS at APP Pharmaceuticals
News Nov 28, 2007
Thermo Fisher Scientific Inc. has announced that it has been selected by APP Pharmaceuticals Inc. for a three site multi-phase rollout of Thermo Scientific Darwin LIMS.
Darwin, a purpose-built laboratory information management system (LIMS) for pharmaceutical manufacturing R&D and QA/QC, will be deployed in all three of APP's manufacturing facilities located in New York, Illinois and Puerto Rico.
APP Pharmaceuticals' products have helped millions of people in the United States and Canada fight critical illnesses by providing a broad portfolio of multi-source and branded injectable pharmaceutical products, including difficult to manufacture and urgently needed medical products. The project is intended to harmonize processes, automate operations and consolidate data management in a single LIMS across all three sites.
The multi-phase project will initially involve the deployment of Darwin's inherent Environmental Monitoring functionality enabling facilities to move from manual systems onto an automated system for microbiological samples from the sterile manufacturing environment.
The second phase of the project will feature an integrated LIMS and Chromatography Data System (CDS) implementation followed by the third phase of the LIMS rollout including SAP interfaces across all sites.
Hector Jimenez, Senior Director of Quality Operations at APP, commented: "We selected Darwin LIMS because it offers purpose-built functionality for pharmaceutical manufacturing - the solution is extremely easy to configure and use for our environmental and our chemistry laboratories. In addition, we are confident that Darwin LIMS will provide efficiency improvements in the tracking of samples and in capabilities of trending data as well as compliance."
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
BioAscent Secures Investment to Expand its Integrated Drug Discovery ServicesNews
£1.6m investment recognises BioAscent’s unique capabilities.READ MORE
GE Focuses Portfolio for Growth and Shareholder Value CreationNews
Healthcare to become standalone company; GE expects to monetize 20% and distribute remaining 80% of GE Healthcare to shareholders tax-free.READ MORE